Postow says there have been algorithms developed over recently years to determine patient's toxicities and prescribe certain immunosupressive treatments to help abate the symptoms.
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering, discusses toxicities associated with checkpoint blockades. Postow says there have been algorithms developed over recently years to determine patient's toxicities and prescribe certain immunosupressive treatments to help abate the symptoms.
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
2 Commerce Drive
Cranbury, NJ 08512